Linda Manwaring

Linda Manwaring

Auto-generated profile, based on publicly available information

Linda Manwaring

Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Genetics in Medicine
Verified
Journal Article
Closed access
DLDawn A. Laney
Dawn A. Laney
DPDawn S. Peck
Dawn S. Peck
AAAndrea M. Atherton
Andrea M. Atherton
LMLinda P. Manwaring
Linda P. Manwaring
KCKatherine M. Christensen
Katherine M. Christensen
RHRobert J. Hopkin
Robert J. Hopkin

2 March 2017 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
DBDustin Baldridge
Dustin Baldridge
JHJennifer Heeley
Jennifer Heeley
MVMarisa Vineyard
Marisa Vineyard
LMLinda Manwaring
Linda Manwaring
TTTomi L. Toler
Tomi L. Toler
MSMarwan Shinawi
Marwan Shinawi
Purpose: Evaluation of the clinician’s role in the optimal interpretation of clinical exome sequencing (ES) results. Methods: Retrospective chart review of the first 155 patients who underwent clinical ES in our Exome Clinic and direct interaction with the ordering geneticist to evaluate the process of interpretation of results. Results: The most common primary indication was neurodevelopmental problems (~66%), followed by multiple congenital anomalies (~10%). Based on sequencing data, the overall diagnostic yield was 36%. After assessment by the medical geneticist, incorporation of detailed phenotypic and molecular data, and utilization of additional diagnostic modalities, the final diagnostic yield increased to 43%. Seven patients in our cohort were included in initial case series that described novel genetic syndromes, and 23% of patients were involved in subsequent research studies directly related to their results or involved in efforts to move beyond clinical ES for diagnosis. Clinical management was directly altered due to the ES findings in 12% of definitively diagnosed cases. Conclusions: Our results emphasize the usefulness of ES, demonstrate the significant role of the medical geneticist in the diagnostic process of patients undergoing ES, and illustrate the benefits of postanalytical diagnostic work-up in solving the “diagnostic odyssey.” Genet Med advance online publication 02 March 2017

1 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
BMBess A Marshall
Bess A Marshall
MPM Alan Permutt
M Alan Permutt
APAlexander R Paciorkowski
Alexander R Paciorkowski
JHJames Hoekel
James Hoekel
RKRoanne Karzon
Roanne Karzon
TGthe Washington University Wolfram Study Group
the Washington University Wolfram Study Group
Wolfram Syndrome (WFS:OMIM 222300) is an autosomal recessive, progressive, neurologic and endocrinologic degenerative disorder caused by mutations in the WFS1 gene, encoding the endoplasmic reticulum (ER) protein wolframin, thought to be involved in the regulation of ER stress. This paper reports a cross section of data from the Washington University WFS Research Clinic, a longitudinal study to collect detailed phenotypic data on a group of young subjects in preparation for studies of therapeutic interventions. Eighteen subjects (ages 5.9-25.8, mean 14.2 years) with genetically confirmed WFS were identified through the Washington University International Wolfram Registry. Examinations included: general medical, neurologic, ophthalmologic, audiologic, vestibular, and urologic exams, cognitive testing and neuroimaging. Seventeen (94%) had diabetes mellitus with the average age of diabetes onset of 6.3 ± 3.5 years. Diabetes insipidus was diagnosed in 13 (72%) at an average age of 10.6 ± 3.3 years. Seventeen (94%) had optic disc pallor and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired vibration sensation. Enuresis was reported by four (22%) and nocturia by three (17%). Of the 11 tested for bladder emptying, five (45%) had elevated post-void residual bladder volume. WFS causes multiple endocrine and neurologic deficits detectable on exam, even early in the course of the disease. Defects in olfaction have been underappreciated. The proposed mechanism of these deficits in WFS is ER stress-induced damage to neuronal and hormone-producing cells. This group of subjects with detailed clinical phenotyping provides a pool for testing proposed treatments for ER stress. Longitudinal follow-up is necessary for establishing the natural history and identifying potential biomarkers of progression.

23 August 2016 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
DSDDD Study
DDD Study
EPE E Palmer
E E Palmer
TST Stuhlmann
T Stuhlmann
SWS Weinert
S Weinert
EHE Haan
E Haan
VKVera Kalscheuer
Vera Kalscheuer
Variants in CLCN4, which encodes the chloride/hydrogen ion exchanger CIC-4 prominently expressed in brain, were recently described to cause X-linked intellectual disability and epilepsy. We present detailed phenotypic information on 52 individuals from 16 families with CLCN4-related disorder: 5 affected females and 2 affected males with a de novo variant in CLCN4 (6 individuals previously unreported) and 27 affected males, 3 affected females and 15 asymptomatic female carriers from 9 families with inherited CLCN4 variants (4 families previously unreported). Intellectual disability ranged from borderline to profound. Behavioral and psychiatric disorders were common in both child- and adulthood, and included autistic features, mood disorders, obsessive–compulsive behaviors and hetero- and autoaggression. Epilepsy was common, with severity ranging from epileptic encephalopathy to well-controlled seizures. Several affected individuals showed white matter changes on cerebral neuroimaging and progressive neurological symptoms, including movement disorders and spasticity. Heterozygous females can be as severely affected as males. The variability of symptoms in females is not correlated with the X inactivation pattern studied in their blood. The mutation spectrum includes frameshift, missense and splice site variants and one single-exon deletion. All missense variants were predicted to affect CLCN4’s function based on in silico tools and either segregated with the phenotype in the family or were de novo. Pathogenicity of all previously unreported missense variants was further supported by electrophysiological studies in Xenopus laevis oocytes. We compare CLCN4-related disorder with conditions related to dysfunction of other members of the CLC family.

24 November 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
BZBin Zhang
Bin Zhang
MWMarcia Willing
Marcia Willing
DGDorothy K. Grange
Dorothy K. Grange
MSMarwan Shinawi
Marwan Shinawi
LMLinda Manwaring
Linda Manwaring
CCCatherine E. Cottrell
Catherine E. Cottrell

11 August 2015 in Journal of Medical Genetics
Verified
Journal Article
Closed access
CDCori DeSanto
Cori DeSanto
KDKristin D'ACo
Kristin D'ACo
GAGabriel C Araujo
Gabriel C Araujo
NSNora Shannon
Nora Shannon
DSDDD Study
DDD Study
MSMarwan Shinawi
Marwan Shinawi
Background: Rare de novo mutations have been implicated as a significant cause of idiopathic intellectual disability. Large deletions encompassing 10p11.23 have been implicated in developmental delay, behavioural abnormalities and dysmorphic features, but the genotype–phenotype correlation was not delineated. Mutations in WAC have been recently reported in large screening cohorts of patients with intellectual disability or autism, but no full phenotypic characterisation was described. Methods: Clinical and molecular characterisation of six patients with loss-of-function WAC mutations identified by whole exome sequencing was performed. Clinical data were obtained by retrospective chart review, parental interviews, direct patient interaction and formal neuropsychological evaluation. Results: Five heterozygous de novo WAC mutations were identified in six patients. Three of the mutations were nonsense, and two were frameshift; all are predicted to cause loss of function either through nonsense-mediated mRNA decay or protein truncation. Clinical findings included developmental delay (6/6), hypotonia (6/6), behavioural problems (5/6), eye abnormalities (5/6), constipation (5/6), feeding difficulties (4/6), seizures (2/6) and sleep problems (2/6). All patients exhibited common dysmorphic features, including broad/prominent forehead, synophrys and/or bushy eyebrows, depressed nasal bridge and bulbous nasal tip. Posteriorly rotated ears, hirsutism, deep-set eyes, thin upper lip, inverted nipples, hearing loss and branchial cleft anomalies were also noted. Conclusions: Our case series show that loss-of-function mutations in WAC cause a recognisable genetic syndrome characterised by a neurocognitive phenotype and facial dysmorphism. Our data highly suggest that WAC haploinsufficiency is responsible for most of the phenotypic features associated with deletions encompassing 10p11.23.